Genetically informed lung cancer medicine

TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells

(2010) Vijay Ramakrishnan et al.   AMERICAN JOURNAL OF HEMATOLOGY

A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes

(2010) Debora Fumagalli et al.   BMC CANCER

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity

(2010) J. W. Tyner et al.   CANCER RESEARCH

Kinases as targets in the treatment of solid tumors

(2010) Georgios Giamas et al.   CELLULAR SIGNALLING

A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2

(2010) J. P. Eder et al.   CLINICAL CANCER RESEARCH

Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases

(2010) S. E. Baldus et al.   CLINICAL CANCER RESEARCH

Targeting Wnt Signaling: Can We Safely Eradicate Cancer Stem Cells?

(2010) F. Takahashi-Yanaga et al.   CLINICAL CANCER RESEARCH

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

(2010) Dora Dias-Santagata et al.   EMBO Molecular Medicine

Analysis of Potential Predictive Markers of Cetuximab Benefit in BMS099, a Phase III Study of Cetuximab and First-Line Taxane/Carboplatin in Advanced Non–Small-Cell Lung Cancer

(2010) Shirin Khambata-Ford et al.   JOURNAL OF CLINICAL ONCOLOGY

The mutation spectrum revealed by paired genome sequences from a lung cancer patient

(2010) William Lee et al.   NATURE

Diverse somatic mutation patterns and pathway alterations in human cancers

(2010) Zhengyan Kan et al.   NATURE

mTOR signaling and drug development in cancer

(2010) Janet Dancey   Nature Reviews Clinical Oncology

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes

(2010) Irene Lurkin et al.   PLoS One

B-RAF Inhibitors: An Evolving Role in the Therapy of Malignant Melanoma

(2010) Cynthia Shepherd et al.   Current Oncology Reports

Emerging Technologies for Assessing HER2 Amplification

(2009) Frédérique Penault-Llorca et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Regulator of G-protein signaling (RGS) proteins in cancer biology

(2009) Jillian H. Hurst et al.   BIOCHEMICAL PHARMACOLOGY

TheEML4-ALKfusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-typeEGFRandKRAS

(2009) Daisy Wing-Sze Wong et al.   CANCER

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

PIK3CA Mutation Associates with Improved Outcome in Breast Cancer

(2009) K. Kalinsky et al.   CLINICAL CANCER RESEARCH

KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

(2009) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers

(2009) Guang Jin et al.   LUNG CANCER

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

(2009) David A. Barbie et al.   NATURE

Requirement for NF-κB signalling in a mouse model of lung adenocarcinoma

(2009) Etienne Meylan et al.   NATURE

A small-cell lung cancer genome with complex signatures of tobacco exposure

(2009) Erin D. Pleasance et al.   NATURE

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

(2009) Wenjun Zhou et al.   NATURE

Factors underlying sensitivity of cancers to small-molecule kinase inhibitors

(2009) Pasi A. Jänne et al.   NATURE REVIEWS DRUG DISCOVERY

Sequencing technologies — the next generation

(2009) Michael L. Metzker   NATURE REVIEWS GENETICS

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer

(2009) Simon A. Forbes et al.   NUCLEIC ACIDS RESEARCH

An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors

(2009) D Chitale et al.   ONCOGENE

Janus Kinase Mutations

(2009) Ross L. Levine   SEMINARS IN ONCOLOGY

Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer

(2008) C. A. Pratilas et al.   CANCER RESEARCH

Novel MEK1 Mutation Identified by Mutational Analysis of Epidermal Growth Factor Receptor Signaling Pathway Genes in Lung Adenocarcinoma

(2008) J. L. Marks et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non-Small Cell Lung Cancer

(2008) Y. L. Choi et al.   CANCER RESEARCH

Multiplex Reverse Transcription-PCR Screening for EML4-ALK Fusion Transcripts

(2008) K. Takeuchi et al.   CLINICAL CANCER RESEARCH

Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

(2008) D. B. Costa et al.   CLINICAL CANCER RESEARCH

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

(2008) G. J. Riely et al.   CLINICAL CANCER RESEARCH

Lung Cancer with Epidermal Growth Factor Receptor Exon 20 Mutations Is Associated with Poor Gefitinib Treatment Response

(2008) J.-Y. Wu et al.   CLINICAL CANCER RESEARCH

Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with EGFR-Mutant Lung Adenocarcinoma

(2008) J. Bean et al.   CLINICAL CANCER RESEARCH

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

(2008) Vincent A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

(2008) T L Lasho et al.   LEUKEMIA

Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia

(2008) L S Steelman et al.   LEUKEMIA

Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond

(2008) Marc Ladanyi et al.   MODERN PATHOLOGY

Somatic mutations affect key pathways in lung adenocarcinoma

(2008) Li Ding et al.   NATURE

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

(2008) Jeffrey A Engelman et al.   NATURE MEDICINE

AKT1 E17K in human solid tumours

(2008) F E Bleeker et al.   ONCOGENE